Goldman Sachs Group initiated coverage on shares of Henry Schein (NASDAQ:HSIC) in a research report sent to investors on Saturday. The firm issued a hold rating and a $78.00 price target on the stock.
A number of other research firms also recently issued reports on HSIC. Craig Hallum boosted their target price on shares of Henry Schein from $83.00 to $96.00 and gave the company a buy rating in a research report on Tuesday, August 7th. Zacks Investment Research upgraded shares of Henry Schein from a hold rating to a buy rating and set a $85.00 target price on the stock in a research report on Tuesday, July 10th. BidaskClub downgraded shares of Henry Schein from a buy rating to a hold rating in a research report on Friday, August 10th. Morgan Stanley boosted their target price on shares of Henry Schein from $65.00 to $66.00 and gave the company an underweight rating in a research report on Tuesday, October 9th. Finally, Leerink Swann set a $100.00 target price on shares of Henry Schein and gave the company a buy rating in a research report on Tuesday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Henry Schein currently has an average rating of Hold and an average target price of $83.53.
Henry Schein stock opened at $82.04 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.68 and a current ratio of 1.29. Henry Schein has a 12-month low of $62.56 and a 12-month high of $90.52. The firm has a market cap of $12.63 billion, a P/E ratio of 22.79, a P/E/G ratio of 2.37 and a beta of 0.97.
Henry Schein (NASDAQ:HSIC) last released its earnings results on Monday, August 6th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.01 by $0.03. Henry Schein had a net margin of 3.15% and a return on equity of 20.40%. The company had revenue of $3.33 billion for the quarter, compared to the consensus estimate of $3.31 billion. During the same quarter in the previous year, the company earned $0.88 EPS. Henry Schein’s quarterly revenue was up 8.7% compared to the same quarter last year. On average, equities research analysts expect that Henry Schein will post 4.12 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the business. Gabelli Funds LLC increased its stake in Henry Schein by 3.5% during the 2nd quarter. Gabelli Funds LLC now owns 343,900 shares of the company’s stock valued at $24,981,000 after purchasing an additional 11,600 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in Henry Schein during the 2nd quarter valued at $371,000. Point72 Asset Management L.P. increased its stake in Henry Schein by 2,573.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 802,047 shares of the company’s stock valued at $58,261,000 after purchasing an additional 772,047 shares in the last quarter. Millennium Management LLC increased its stake in Henry Schein by 60.6% during the 1st quarter. Millennium Management LLC now owns 33,082 shares of the company’s stock valued at $2,223,000 after purchasing an additional 12,482 shares in the last quarter. Finally, JLB & Associates Inc. increased its stake in Henry Schein by 1.9% during the 3rd quarter. JLB & Associates Inc. now owns 55,818 shares of the company’s stock valued at $4,746,000 after purchasing an additional 1,051 shares in the last quarter.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.